Study S002139

A Randomised, Double Blind, Placebo Controlled, Single Centre, 60 Week Trial of Exenatide Once Weekly for the Treatment of Moderate Severity Parkinson's Disease

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT01971242
Acronym: EXENATIDE-PD
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE2
Masking: TRIPLE
Status: COMPLETED
Enrollment: 60
Start: 2014-06
Primary completion: 2016-05
Lead sponsor: University College, London
Conditions: Parkinson's Disease
Interventions: DRUG:Exenatide; OTHER:Placebo
Results posted: FALSE
Individual participant data sharing: NO

Registered primary outcomes

Efficacy [60 weeks]

Linked records (2)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0012158	GLP1 receptor agonism ameliorates Parkinson’s disease through modulation of neuronal insulin signalling and glial suppression Athauda D, bioRxiv	2024	Other trial	DOI	cites ClinicalTrials.gov:NCT01971242
R0022561	Exenatide once weekly versus placebo in Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Athauda D, Lancet (London, England)	2017	Randomized trial	PMID 28781108 DOI	cites ClinicalTrials.gov:NCT01971242; registry reference DERIVED:28781108